Join us Sept. 14-16 in Miami to connect with top publishing leaders
Subscribe: iTunes | Google Play | Stitcher | RSS | Anchor
Making Marketing is making some changes. Starting with our very next episode, we’ll be the Modern Retail Podcast, bringing you conversations with people innovating in retail, including the oh-so-buzzy world of DTC.
But before that, this episode rounds up a few highlights from Making Marketing’s interviews in the past year:
Kevin Lavelle, the founder of menswear brand Mizzen and Main
“I’ve spoken with a couple VC firms. We had positive feedback, but one VC said she couldn’t see how we could [make] 10 times our revenue over the next 12-18 months, so they’re not interested. And it stuck with me. She was absolutely right.”
Rachel Drori, founder of the subscription frozen food company Daily Harvest
“I have such issues with what I call the cycle of torching cash. What’s happening is that there’s so much VC money out there — anybody can raise — and then they can throw money at their problems.”
Joe Kudla, founder of athleisure brand Vuori
“If you go straight to the VC community pre-revenue, they’re going to dictate terms often terms. You don’t want a VC running your business.”
Jed Berger, CMO at Foot Locker
“I think that it’s an interesting time, and in many companies, there needs to be a redefinition of the role of the CMO, or marketing within the organization, or how it reports, or what its accountabilities are. The marketing industry is in for an evolution.”
More in Marketing
Future of Marketing Briefing: The public ad tech era is over
Gone are the days when investors got themselves in a tizzy over ad networks, demand-side platforms and supply-side platforms on their own merits.
By the numbers: Wall Street’s tough assessment of ad tech
Big Tech continues to dominate digital growth, triggering a Wall Street exodus, but are returns imminent?
CMOs are struggling to link AI visibility with sales
Brands are spending on tools that rate their visibility within LLM responses and AI search, but proving the commercial impact of GEO remedies isn’t easy.